We have established an extracorporeal bowel model system for the analysis of early events in inflammatory bowel disease (IBD) and therapeutic applications. This model consists of an intestinal segment that is cannulated and perfused in situ, allowing the investigation of cellular responses of apical mucosa cells on luminale applied substances. Short-term treatment with iodoacetamide mimicked experimental intestinal inflammation in IBD indicated by histological alterations, such as hemorrhage, hyperemia and loss of regular crypt architecture as well as enhanced expression of cytokines (e.g. IL-6, IL-10 and MCP-1) compared to control segments perfused with media. Perfusion of therapeutic agents (e.g. dexamethasone or Mutaflor) in the small intestine segment significantly reduced the features of early inflammation induced by iodoacetamide. Moreover, similar data were obtained for Resormin®, a montmorillonite-illite mixed layer mineral (smectite), indicating that smectite might be a novel therapeutic option for IBD. In summary, this model may provide novel insights into epithelial injury as well as genesis of IBD and, therefore, be useful in testing the therapeutic potential of compounds for IBD therapy.
- Received January 15, 2013.
- Accepted August 8, 2013.
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial Share Alike License (http://creativecommons.org/licenses/by-nc-sa/3.0), which permits unrestricted non-commercial use, distribution and reproduction in any medium provided that the original work is properly cited and all further distributions of the work or adaptation are subject to the same Creative Commons License terms.